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Article Information  ABSTRACT 
Received: 12th June 2019  Liposomes are the spherical vesicles containing one or more phospholipid bilayer, which was 
first described in the middle of 60s by Bangham. The bilayer vesicles are considered as an 
efficient carrier for drug delivery, diagnostic agents, and also an effective tool for vaccine 
delivery.  Liposome has been used as a potential carrier for several diseases from cardiovascular 
disease to bacterial infection and also it has the ability to reducing the toxicity of highly potent 
drugs and simultaneously utilized to improve pharmacokinetics and therapeutic efficacy. A 
liposome is a formulation which has the capacity to overcome with the limitation of conventional 
therapies. For the delivery of liposome ocular and inhalation route are some advanced 
technology. In poorly water soluble substance pulmonary delivery is very much useful. However 
liposome based vaccines have been demonstrated in clinical trials and further progress in human 
trails. This review discusses the mechanism of action, Method of preparation, evaluation, 
application of liposomal drug delivery system along with the recent developments some of the 
commercially available products. 
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INTRODUCTION 
English hematologist Alec Bangham in 1961, first being 
described artificial lipid vesicles (also called liposomes). It has 
been recognized and extensively used as delivery vehicles for 
pharmaceuticals, as chemical microreactors, and as model 
biomembrane systems [1]. Liposome can be processed and 
formulated to differ in composition, charge, size and 
lamellarity [2]. Further liposome may be described as 
concentric bilayered vesicles within which associate degree 
binary compound core is entirely encapsulated by a 
membranous lipid bilayer principally composed of natural or 
artificial lipid. The size of a vesicle ranges from some 20 nm 
up to many micrometers. The lipid molecules square measure 
sometimes lipid amphipathic moieties with a hydrophobic tail. 
On the addition of excess water, such lipid moieties 
spontaneously originate to offer the most thermodynamically 
stable conformation. Where,  polar head teams face outwards 
into the binary compound medium and therefore the lipid 
chains turns inward to avoid the water section, giving rise to 
double layer or atomic number 83 layer lamellar structures.  
 
Structural components of liposomes-[3, 4, 5] 
• The main components of liposomes are-  
1. Phospholipids  2. Cholesterol 
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Fig. 1 inside and outside view of liposome 
 
Phospholipid 
 
 
Chemical structure of phosphoglycerides and 
sphingolipids: 
 
Fig 2: chemical structure of phosphoglycerides and 
sphingolipids 
 
Phosphatidylcholine- The most common phospholipids used 
is phosphatidylcholine (PC), an amphipathic molecule, which 
consists of a hydrophilic polar head group, phosphocholine, a 
glycerol bridge and a pair of hydrophobic acyl hydrocarbon 
chains.  
 
Cholesterol - Cholesterol is a waxy, fat-like substance is an 
essential component of our body. It helps to produce hormones, 
vitamin D, and substances that help to digest foods. Cholesterol 
itself does not form a bilayer structure. It acts as fluidity 
buffer.it interacts with phospholipid molecules and alters the 
mobility of carbon molecules in the acyl chain and Restricts the 
transformations of Trans to gauche conformations. 
Cholesterol incorporation increases the separation between 
choline head group & eliminates normal electrostatic & 
hydrogen bonding interactions. 
 
Mechanism of liposome formation- 
Liposome is composed of phospholipids. The hydrophilic part 
is mainly phosphoric acid bound to a water-soluble molecule, 
whereas the hydrophobic part consists of two fatty acid chains 
with carbon atoms 10-24 and double bonds 0-6 in each chain. 
An aqueous environment the phospholipid orient themselves to 
form bilayer where one layer of the phospholipid faces outside 
of the cells whereas another layer of the phospholipid faces 
inside the cell to avoid the water phase. The hydrocarbon tail of 
one layer faces the hydrocarbon tail of another layer and 
combines to form bilayer this structure is also called lamella. 
Upon further hydration, the lipid cake (lamella) swells 
eventually that curves to form closed vesicles in the form of 
spheres known as a liposome. [6] 
Fig.3 Mechanism of action of liposome 
A Lamella is a flat plate-like structure that appears during the 
formation of a liposome. The phospholipids bilayer first exists 
as a lamella before getting converted into spheres. Several 
lamella of phospholipids bilayer are stacked one on top of the 
other during the formation of liposome to form a multilamellar 
structure. 
 
Table 1: Advantages &disadvantages of liposome- [7, 8, 9] 
Advantages Disadvantages 
Liposome increased efficacy 
and therapeutic index of drug 
Sometimes phospholipid 
underdogs oxidation and 
hydrolysis like reaction 
Liposome is non-toxic, flexible, 
biocompatible, completely 
biodegradable and non-
immunogenic for systemic and 
non-systemic administration 
Drug leakage/ entrapment/ 
drug fusion 
 
Liposome increase stability via 
encapsulated drug. 
Biological activity is short / 
t ½ 
Liposome reduced the toxicity 
of the encapsulated agent. 
Low solubility and 
oxidation off bilayer 
phospholipid 
Liposome reduce the exposure 
of sensitive tissue to toxic drugs 
Rate of release and altered 
biodistribution 
Improved pharmacokinetic 
effects (reduced elimination 
increased circulation lifetimes) 
Low therapeutic index and 
dose effectiveness 
Suitable for controlled release Repeated IV administration 
problems  
 
Classification- [7, 10]
 
1. Based on structural parameters 
a. MLV: Multi lamellar vesicle (0.5     ) 
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b. OLV: Oligolamellar vesicle (0.1-1    ) 
c. UV: Unilamellar vesicle (All size range) 
d. SUV: Small unilamellar vesicle (30-70 nm) 
e. MUV: Medium sized unilamellar vesicle 
f. LUV: Large unilamellar vesicle          ) 
g. GUV: Giant unilamellar vesicle (      ) 
2. Based on the method of preparation 
a. REV: Reverse phase evaporation vesicles 
b. MLV-REV: Multi lamellar vesicle by REV 
c. DRV: Dehydration- rehydration method 
d. VET : Vesicle prepared by extraction method 
e. SPLV: Stable plurilamellar vesicles 
f. FATMLV: Frozen and thawed MLV 
3. Based on composition of application 
a. Conventional liposome 
b. Fusogenic liposomes 
c. Ph sensitive liposomes 
d. Cationic liposomes 
e. Long circulatory liposome 
f. Immuno liposomes 
 
Method of preparation-  [8, 11, 12, 13, 14]  
 
Hand shaking MLVs      
It is the most common and simple method used for the 
preparation of MLVs. In these processes, the lipids are 
dissolved in solvents (choloroform: methanol) which are then 
transfer to a round bottom flask. The RBF containing the 
mixture is then attached to rotary evaporator and then it was 
rotated at 60 rpm until a dry thin layer is formed after that it is 
dried in lyophilizer to remove the last traces of solvent and it is 
hydrated with phosphate buffer saline containing the material 
to be entrapped and then it was attached to rotary evaporator at 
60 rpm or below it was rotated until the layer adhering on the 
wall of the RBF is removed and it was kept stand at room 
temperature for 2 h upon hydration milky white disperse 
appear. 
 
 
Fig. 4 method of handshaking 
 
Non-hand shaking LUVs- 
In these methods lipid mixed with solvent is spread over the 
conical flask and the solution is evaporated at room 
temperature without disturbing by the flow of nitrogen. After 
the solution gets dried it is hydrated by water-saturated 
nitrogen which is passed through the conical flask until the 
opacity of dried lipid film disappears. After hydration, the lipid 
gets swelled. Then the flask is inclined to one side and 10 to 20 
ml of 0.2 M sucrose in distilled water is added to the side of the 
flask and then the flask is slowly returned to its original 
position. The fluid gently runs over the lipid layer on the 
bottom of the flask. Then the flask is flushed with nitrogen and 
sealed it was then allowed to stand for 2 h at room temperature. 
After swelling the suspension is centrifuged at 12000 g for 10 
min at room temperature. The remaining fluid add iso-osmolar 
glucose solution then LUVs formed 
 
Freeze drying method - 
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In these method lipid and solvent are mixed and evaporate at 
room temperature by flow of nitrogen for drying. Then add 
some water saturated nitrogen until opacity disappears. Add 
water fluid and 10-20 ml of 0.2 M sucrose solution to swell. 
After that stand for 2 hour at 37 c then centrifuged at 12000 
rpm for 10 min at room temperature and reaming fluid are add 
to iso-osmolar glucose solution to formed LUVs 
 
Membrane extrusion- 
In this technique vesicles contents are exchanged with 
dispersion medium during breaking and resealing of phosphate 
lipid bilayer as they pass through polycarbonate membrane and 
less pressure is required here as compare to French pressure 
cell then  use to process MLVs and LUVs. At last tortuous and 
nucleation trach membrane are formed. 
  
Fig. 5 method of membrane extrusion 
Dehydration rehydration method 
In these technique, liposomal suspension was prepared by THF 
are frozen in liquid nitrogen then freeze-dried overnight. After 
hydration with water, the liposome is prepared. 
 
Sonication method 
In this method surfactant and cholesterol are mixed in 2 ml of 
the aqueous phase in a vial and then the mixture is sonicated 
for 3 min at 60 c using titanium probe sonicator after that 
unilamellar vesicle is formed (Fig. 6). 
 
Reverse phase evaporation method (REV) 
The lipid mixture is taken in a round bottom flask followed by 
removal of the solvent under reduced pressure by a rotary 
evaporator. The system is purged with nitrogen and the lipids 
are re-dissolved in the organic phase. The reverse-phase 
vesicles will form in this phase. The usual solvents used are 
diethyl ether and isopropyl ether. An aqueous phase which 
contains the drug to be encapsulated is added after the lipids 
are re-dispersed in this phase. The system is kept under 
continuous nitrogen and the two-phase system is sonicated until 
the mixture becomes clear one-phase dispersion. The mixture is 
then placed on the rotary evaporator and the removal of organic 
solvent is done until a gel is formed followed by the removal of 
non-encapsulated material. The resulting liposomes are called 
reverse-phase evaporation vesicles (Fig. 7) 
 
 
Fig. 6 method of sonication 
 
Dried reconstitute vesicle 
Here the preformed liposomes are rehydrated to an aqueous 
fluid containing an active ingredient which is followed by 
dehydration of the mixture (Fig 8) 
 
French pressure cell 
The liposomes prepared by this technique are less likely to 
suffer from the structural defect and instability as observed in 
the sonicated vesicle. Leakage of contents from liposome 
preparing using French press is slower and slower than 
sonicated liposome. It has used to reduce the heterogeneity of 
populations of proteoliposomes obtained by detergent dialysis 
technique. 
The method has several advantages over the sonication method. 
The method is simple rapid, reproducible and involving gentle 
handling of unstable materials. The resulting liposome is 
somewhat larger than sonicated SUVs. The main drawback of 
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the method is that the temperature is difficult to achieve and the 
working volume is relatively small. 
 
Fig. 7 Method of reverse phase evaporation 
 
Evaluation of liposome
 
[12, 15] 
The characterization parameters for purpose of evaluation 
could be classified into three categories which  
are physical, chemical and biological parameters. 
Table no 2 Physical characterization 
Characterization parameter Analytical method/ instrument 
Vesicle shape and surface 
morphology 
Transmission electron 
microscopy, freeze- fracture 
electron microscopy 
Surface charge Free flow electrophoresis 
Mean vesicle size and size 
distribution 
Photon correlation 
spectroscopy, laser light 
scattering, gel permeation and 
gel exclusion 
Lamellarity Small angle X- ray scattering, 
31 P-NMR,, Freeze fracture 
electron microscopy 
Electrical surface potential 
and surface pH 
Zeta potential measurement 
Phase behavior Freeze fracture electron 
microscopy, Differential 
scanning calorimetry 
Percent of free drug/ percent 
capture 
Minicolumn centrifugation, ion-
exchange chromatography. 
Table no 3 Chemical characterization 
Characterization parameter Analytical method/ instrument 
Phospholipid concentration Lipid phosphorous content using 
barlet assay, HPLC 
Cholesterol concentration Cholesterol oxidized assay and 
HPLC 
Drug concentration Appropriate methods given in 
monograph for individual drug 
Phospholipid peroxidation UV absorbance TBA iodometric 
and GLC 
Phospholipid hydrolysis HPLC and TLC and fatty acid 
concentration 
Phospholipid auto 
oxidation 
HPLC and TLC 
Anti-oxidant degradation HPLC and TLC 
pH pH meter 
 
Table no 4 Biological characterization 
Parameters Analytical method/ instrument 
Sterility Aerobic or anaerobic cultures 
Pyrogenicity Limulus Amebocyte Lysate (LAL) test 
Animal 
toxicity 
Monitoring survival rates, histology and 
pathology 
 
Application of liposome [16, 18 – 20] 
Application of liposome in pharmacology and medicine can be 
distinguished between diagnostic and therapeutic application of 
liposome. That containing various drug or markers, and their 
use as a tool, a reagent or a model in the basic studies of 
interaction of cell, recognition processes, and mode of action of 
certain substances. Unfortunately, many drugs have a very 
narrow therapeutic window, meaning is to the therapeutic 
concentration is not much lower than the toxic one. In various 
cases, the efficacy can be enhanced or the toxicity can be 
reduced by the use of a suitable drug carrier which alters the 
spatial and temporal delivery of the drug, i.e., its 
pharmacokinetics and bio distribution. It is clear from many 
pre-clinical and clinical studies that drugs, for instance 
antitumor drugs, parceled in liposome demonstration reduced 
toxicities, while retentive enhanced efficacy. 
 
Liposomes in parasitic diseases and infections 
From the time when conventional liposomes are digested by 
phagocytic cells in the body after intravenous management, 
they are ideal vehicles for the targeting drug molecules into 
these macrophages. The best known instances of this ‘Trojan 
horse like mechanism are several parasitic diseases which 
Journal of Applied Pharmaceutical Research 8 (1); 2020: 22 – 28 Sonowal et. al  
 
 
  Journal of Applied Pharmaceutical Research (JOAPR)| January – March 2020 | Volume 8 Issue 1 |   27 
normally exist in the cell of MPS. They comprise leishmaniasis 
and several fungal infections. 
 
Cancer therapy 
Liposomes are successfully used to entrap anticancer drugs. 
This increases circulation life time, protect from metabolic 
degradation 
 
Liposome as carrier of drug in oral treatment 
 Steroids used for arthritis can be incorporated into large 
MLVs. 
 Alteration in blood glucose levels in diabetic animals was 
obtained by oral administration of liposome-encapsulated 
insulin. 
 
Liposome for topical application 
 Drugs like triamcinolone, benzocaine, corticosteroids, etc. 
can be successfully incorporated as a topical liposome. 
 
Liposome for pulmonary delivery- 
 Inhalation devices like nebulizer are used to produce an 
aerosol of droplets containing liposomes. 
 
Enhanced antimicrobial efficacy or safety 
Antimicrobial agents have been encapsulated in liposomes for 
two reasons. 
 First, they protect the entrapped drug against enzymatic 
degradation. For instance, the penicillin and cephalosporin 
are sensitive to the derivative action of J-lactamase, which 
is produced by certain microorganisms.  
 Secondly, the lipid nature of the vesicles promotes 
enhanced cellular uptake of the antibiotics into the 
microorganisms, thus reducing the effective dose and the 
incidence of toxicity as exemplified by the liposomal 
formulation of amphotericin B. 
 
CONCLUSION 
Several drug candidates which are highly potent and have low 
therapeutic indication can be targeted to the required diseased 
site using the liposomal drug delivery system. Drugs 
encapsulated in liposomes can have a significantly altered 
pharmacokinetics. Liposomes have been used in a broad range 
of pharmaceutical applications. Liposomes are showing 
particular promise as intracellular delivery systems for anti-
sense molecules, ribosomes, proteins/peptides, and DNA. 
Liposomes with enhanced drug delivery to disease locations, 
by the ability of long circulation residence times, are now 
achieving clinical acceptance. Also, liposomes promote 
targeting of particular diseased cells within the disease site. 
Finally, liposomal drugs exhibit reduced toxicities and retain 
enhanced efficacy compared with free complements. The 
efficacy of the liposomal formulation depends on its ability to 
deliver the drug molecule to the targeted site over a prolonged 
period, only time will tell which of the above applications and 
speculations will prove to be successful. However, based on the 
pharmaceutical applications and available products, we can say 
that liposomes have established their position in the modern 
drug delivery system. 
 
Table 5: FDA approved Marketed product [12, 17, 21-22] 
Drug Disease 
liposomal 
delivery system 
Amphotericin B Anti-fungal prophylaxis Conventional 
Daunorubicin 
Leukemia and solid 
tumors 
Conventional 
Cytarabine or 
cytosine 
arabinoside 
Neoplastic meningitis 
and lymphomatous 
meningitis 
Conventional 
Morphine 
sulphate 
Pain management Conventional 
Verteporfin Molecular degeneration Conventional 
Vincristine 
Non – Hodgkin 
lymphoma 
Conventional 
Doxorubicin 
and bortezomib 
Relapsed or refractory 
multiple myeloma 
PEGylated 
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